Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Upgrade	Baird upgrades Vertex Pharmaceuticals, shares attractive ahead of readouts » 08:16 02/23/21 02/23 08:16 02/23/21 08:16 VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) As reported previously,… As reported previously, Baird analyst Brian Skorney upgraded Vertex Pharmaceuticals to Outperform from Neutral with a price target of $252, up from $220. The analyst said the shares were attractive ahead of several readouts and is supported by the CF opportunity. He said any positive news flow for the pipeline has the potential to provide significant upside to the shares. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/22/21 Vertex study of VX-864 completes enrollment, Clinicaltrials.gov shows 02/16/21 Freeline appoints Michael Parini as president, COO 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/23/21 Baird Vertex Pharmaceuticals upgraded to Outperform from Neutral at Baird 02/02/21 Credit Suisse Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse 02/02/21 BMO Capital Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital 02/02/21 H.C. Wainwright Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
Upgrade	Vertex Pharmaceuticals upgraded to Outperform from Neutral at Baird » 05:27 02/23/21 02/23 05:27 02/23/21 05:27 VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) Baird analyst Brian… Baird analyst Brian Skorney upgraded Vertex Pharmaceuticals to Outperform from Neutral with a price target of $252, up from $220. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/22/21 Vertex study of VX-864 completes enrollment, Clinicaltrials.gov shows 02/16/21 Freeline appoints Michael Parini as president, COO 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/02/21 Credit Suisse Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse 02/02/21 BMO Capital Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital 02/02/21 H.C. Wainwright Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright 02/02/21 Piper Sandler Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA VRTX Vertex Pharmaceuticals $215.14 / +8.05 (+3.89%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
Hot Stocks	Vertex study of VX-864 completes enrollment, Clinicaltrials.gov shows » 12:59 02/22/21 02/22 12:59 02/22/21 12:59 VRTX Vertex Pharmaceuticals $214.90 / +7.81 (+3.77%) Vertex… Vertex Pharmaceuticals' study evaluating the efficacy, safety and pharmacokinetics of VX-864 in subjects with a PiZZ genotype has completed enrollment, according to an update on Clinicaltrials.gov. STAT's Adam Feuerstein tweeted:" $VRTX VX-864 clinical trial patient enrollment completed, suggesting no liver tox issues." Shares of Vertex are up 4% to $215.40 in afternoon trading. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX Vertex Pharmaceuticals $214.90 / +7.81 (+3.77%) 02/16/21 Freeline appoints Michael Parini as president, COO 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion VRTX Vertex Pharmaceuticals $214.90 / +7.81 (+3.77%) 02/02/21 Credit Suisse Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse 02/02/21 BMO Capital Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital 02/02/21 H.C. Wainwright Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright 02/02/21 Piper Sandler Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler VRTX Vertex Pharmaceuticals $214.90 / +7.81 (+3.77%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close VRTX Vertex Pharmaceuticals $214.90 / +7.81 (+3.77%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX Vertex Pharmaceuticals $214.90 / +7.81 (+3.77%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA VRTX Vertex Pharmaceuticals $214.90 / +7.81 (+3.77%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
Hot Stocks	Freeline appoints Michael Parini as president, COO » 07:23 02/16/21 02/16 07:23 02/16/21 07:23 FRLN Freeline $15.64 / +0.1 (+0.64%) , VRTX Vertex Pharmaceuticals $214.26 / +3.75 (+1.78%) Freeline Therapeutics… Freeline Therapeutics (FRLN) announced the expansion of its executive leadership team with the appointment of Michael Parini to the newly-created role of President and COO. This appointment complements the recent hires of Stephen Diamond, Jr. as SVP and General Counsel and David Arrington as VP of Investor Relations and Corporate Communications. Michael Parini has been appointed to the role of President and COO, effective March 15, 2021. Parini will be based in the US and will report to CEO. Theresa Heggie, supporting her in executing the Company's global strategy and overseeing critical business and operational functions. These functions include Program Management, Corporate Strategy, Business Development, Legal, Compliance, Investor Relations, Corporate Communications and Information Technology. Parini brings more than 20 years of executive experience in the biopharmaceutical industry, including most recently at Vertex Pharmaceuticals (VRTX), where he served as Executive Vice President and Chief Administrative, Legal and Business Development Officer. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VRTX FRLN VRTX Vertex Pharmaceuticals $214.26 / +3.75 (+1.78%) 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion 12/28/20 Vertex Pharmaceuticals announces new drug submission for Trikafta FRLN Freeline $15.64 / +0.1 (+0.64%) 02/09/21 Aquestive Therapeutics appoints Julie Krop, Marco Taglietti to board 02/08/21 Freeline to highlight data from Gaucher and Fabry disease gene therapy program 02/08/21 Freeline targets initiation of dose confirmation FLT180a trial by end of 2021 12/14/20 Freeline reports updated data from Phase 1/2 B-AMAZE trial FRLN VRTX FRLN Freeline $15.64 / +0.1 (+0.64%) 11/25/20 Redburn Freeline initiated with a Neutral at Redburn 09/01/20 Evercore ISI Freeline initiated with an Outperform at Evercore ISI 09/01/20 Wedbush Wedbush bullish on Freeline, initiates with an Outperform 09/01/20 Wedbush Freeline initiated with an Outperform at Wedbush VRTX Vertex Pharmaceuticals $214.26 / +3.75 (+1.78%) 02/02/21 Credit Suisse Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse 02/02/21 BMO Capital Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital 02/02/21 H.C. Wainwright Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright 02/02/21 Piper Sandler Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler VRTX VRTX Vertex Pharmaceuticals $214.26 / +3.75 (+1.78%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close 07 Aug VRTX VRTX Vertex Pharmaceuticals $214.26 / +3.75 (+1.78%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX VRTX Vertex Pharmaceuticals $214.26 / +3.75 (+1.78%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA 02/22/21 Freeline VRTX VRTX Vertex Pharmaceuticals $214.26 / +3.75 (+1.78%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
Periodicals	Amicus, BioMarin speculated by Dealreporter as possible Vertex targets » 10:07 02/02/21 02/02 10:07 02/02/21 10:07 VRTX Vertex Pharmaceuticals $223.16 / -8.55 (-3.69%) , FOLD Amicus $19.25 / + (+0.00%) , BMRN BioMarin $83.36 / +0.26 (+0.31%) Following the latest… Following the latest earnings call from Vertex Pharmaceuticals (VRTX), Dealreporter told its subscribers that questions about what the company is going to buy "do not appear to be going away anytime soon," contacts tell The Fly. The deal-focused publication notes that is has previously highlighted Amicus Therapeutics (FOLD) "as a potential name to keep an eye on" in light of Vertex's previous interest in the gene therapy space, adding that "maybe this is the year that longtime rare disease takeover target" Biomarin Pharmaceutical (BMRN) gets a "serious look" if Vertex "wanted to swing for the fences," contacts tell The Fly. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX FOLD BMRN VRTX Vertex Pharmaceuticals $223.16 / -8.55 (-3.69%) 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion 12/28/20 Vertex Pharmaceuticals announces new drug submission for Trikafta FOLD Amicus $19.25 / + (+0.00%) 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities 01/11/21 Amicus sees 2021 Galafold revenue of at least $300M 01/11/21 Amicus sees Q4 Galafold revenue $70M BMRN BioMarin $83.36 / +0.26 (+0.31%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies VRTX FOLD BMRN VRTX Vertex Pharmaceuticals $223.16 / -8.55 (-3.69%) 02/02/21 Credit Suisse Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse 02/02/21 BMO Capital Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital 02/02/21 H.C. Wainwright Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright 02/02/21 Piper Sandler Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler FOLD Amicus $19.25 / + (+0.00%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List BMRN BioMarin $83.36 / +0.26 (+0.31%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan VRTX FOLD BMRN VRTX Vertex Pharmaceuticals $223.16 / -8.55 (-3.69%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close FOLD Amicus $19.25 / + (+0.00%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) BMRN BioMarin $83.36 / +0.26 (+0.31%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 08/04/20 BioMarin backs FY20 revenue view $1.85B-$1.95B, consensus $1.9B 08/04/20 BioMarin reports Q2 EPS (16c), consensus (11c) VRTX VRTX Vertex Pharmaceuticals $223.16 / -8.55 (-3.69%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX FOLD BMRN VRTX Vertex Pharmaceuticals $223.16 / -8.55 (-3.69%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday FOLD Amicus $19.25 / + (+0.00%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street BMRN BioMarin $83.36 / +0.26 (+0.31%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street 02/02/21 EAHAD 2021 Virtual Congress 02/12/21 17th Annual Virtual WORLDSymposium 2021 00:00 Today 41st Annual Healthcare Virtual Conference 02/25/21 BioMarin - BMRN 06/08/21 PDUFA Date for TRIKAFTA 08/20/21 PDUFA Date for Vosoritide VRTX BMRN VRTX Vertex Pharmaceuticals $223.16 / -8.55 (-3.69%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th BMRN BioMarin $83.36 / +0.26 (+0.31%) 09/18/20 BioMarin call volume above normal and directionally bullish

Recommendations	Vertex Pharmaceuticals price target lowered to $280 from $285 at Credit Suisse » 08:07 02/02/21 02/02 08:07 02/02/21 08:07 VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) Credit Suisse analyst… Credit Suisse analyst Evan Seigerman lowered the firm's price target on Vertex Pharmaceuticals to $280 from $285 and keeps an Outperform rating on the shares following quarterly results. The analyst notes that while Q4 results were "fine" - modest revenue beat, and a slight EPS miss -, investor focus has turned to business development. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion 12/28/20 Vertex Pharmaceuticals announces new drug submission for Trikafta VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/02/21 BMO Capital Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital 02/02/21 H.C. Wainwright Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright 02/02/21 Piper Sandler Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler 01/12/21 Truist Crispr Therapeutics price target raised to $210 from $170 at Truist VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
Recommendations	Vertex Pharmaceuticals price target lowered to $284 from $302 at BMO Capital » 06:57 02/02/21 02/02 06:57 02/02/21 06:57 VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) BMO Capital analyst Do… BMO Capital analyst Do Kim lowered the firm's price target on Vertex Pharmaceuticals to $284 from $302 but keeps an Outperform rating on the shares. The analyst notes that while the company's FY21 product revenue guidance looks "conservative", he is lowering his EPS view to $11.83 from $12.23. Kim still keeps the $10B or more in peak sales estimate for Vertex and believes that its Trikafta/Kaftrio will continue to grow this year. The analyst adds that the company's pipeline progress, starting with VX-86 phase 2 trial data in the first half of this year, could begin adding "pipeline value". ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion 12/28/20 Vertex Pharmaceuticals announces new drug submission for Trikafta VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/02/21 H.C. Wainwright Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright 02/02/21 Piper Sandler Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler 01/12/21 Truist Crispr Therapeutics price target raised to $210 from $170 at Truist 12/30/20 Fly Intel: Top five analyst calls VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
Recommendations	Vertex Pharmaceuticals price target lowered to $275 from $315 at H.C. Wainwright » 06:31 02/02/21 02/02 06:31 02/02/21 06:31 VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) H.C. Wainwright analyst… H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Vertex Pharmaceuticals to $275 from $315 and keeps a Buy rating on the shares to reflect the company's provided revenue guidance for 2021. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion 12/28/20 Vertex Pharmaceuticals announces new drug submission for Trikafta VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/02/21 Piper Sandler Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler 01/12/21 Truist Crispr Therapeutics price target raised to $210 from $170 at Truist 12/30/20 Fly Intel: Top five analyst calls 12/30/20 Daiwa Vertex Pharmaceuticals initiated with an Outperform at Daiwa VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
Recommendations	Vertex Pharmaceuticals price target raised to $347 from $307 at Piper Sandler » 05:06 02/02/21 02/02 05:06 02/02/21 05:06 VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) Piper Sandler analyst… Piper Sandler analyst Edward Tenthoff raised the firm's price target on Vertex Pharmaceuticals to $347 from $307 and reiterates an Overweight rating on the shares following the company's Q4 results. The analyst says "strong" cystic fibrosis sales will fund Vertex's "emerging" early stage pipeline. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion 12/28/20 Vertex Pharmaceuticals announces new drug submission for Trikafta VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 01/12/21 Truist Crispr Therapeutics price target raised to $210 from $170 at Truist 12/30/20 Fly Intel: Top five analyst calls 12/30/20 Daiwa Vertex Pharmaceuticals initiated with an Outperform at Daiwa 12/10/20 Oppenheimer Crispr Therapeutics price target raised to $165 from $155 at Oppenheimer VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 02/01/21 Notable companies reporting after market close 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Fly Intel: After-Hours Movers 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday 00:00 Today 41st Annual Healthcare Virtual Conference 06/08/21 PDUFA Date for TRIKAFTA VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th
On The Fly	Fly Intel: After-Hours Movers » 19:13 02/01/21 02/01 19:13 02/01/21 19:13 SKY Skyline Champion $34.99 / +1.29 (+3.83%) , KMT Kennametal $39.05 / +1.2 (+3.17%) , HLIT Harmonic $7.87 / +0.08 (+1.03%) , CRUS Cirrus Logic $97.99 / +4.155 (+4.43%) , RMBS Rambus $19.55 / +0.51 (+2.68%) , WWD Woodward $115.35 / +3.32 (+2.96%) , VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) , ARQT Arcutis Biotherapeutics $35.37 / +7.95 (+28.99%) , NXPI NXP Semiconductors $171.63 / +11.4 (+7.11%) , MITK Mitek Systems $16.85 / +0.71 (+4.40%) , CURI CuriosityStream $17.80 / +0.39 (+2.24%) , RVMD Revolution Medicines $44.71 / +2.41 (+5.70%) , AXTA Axalta Coating $27.77 / +0.77 (+2.85%) Check out this evening's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options WWD VRTX RVMD RMBS NXPI MITK KMT HLIT CURI CRUS AXTA ARQT WWD Woodward $115.35 / +3.32 (+2.96%) 02/01/21 Woodward boosts quarterly dividend to 16.25c per share 02/01/21 Woodward boosts quarterly dividend to 16.25c per share VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals sees FY21 product revenue $6.7B-$6.9B 01/28/21 Vertex says FDA approves IND application for type 1 diabetes treatment VX-880 01/26/21 Vertex announces FDA accepts sNDA for Trikafta expansion 12/28/20 Vertex Pharmaceuticals announces new drug submission for Trikafta RVMD Revolution Medicines $44.71 / +2.41 (+5.70%) 10/25/20 Revolution Medicines reports progress, expansion of combo strategy with RMC-4630 10/12/20 Revolution Medicines to present interim fata from Phase 1b/2 trial of RMC-4630 09/16/20 Revolution Medicines reports data on KRAS-G12D(ON) inhibitors RMBS Rambus $19.55 / +0.51 (+2.68%) 02/01/21 Rambus sees Q1 licensing billings $60M-$66M 11/12/20 Rambus initiates accelerated $50M share repurchase program 11/02/20 Rambus announces new 20M share repurchase program 10/27/20 Rambus announces availability of 'high-performance IPsec Engine' for 5G traffic NXPI NXP Semiconductors $171.63 / +11.4 (+7.11%) 12/09/20 NXP Semiconductors' Owen sells over 7,000 common shares 12/02/20 NXP Semiconductors reports availability of 2nd genreation RF multichip modules 11/25/20 NXP Semiconductors CEO sells 10K shares of common stock 11/25/20 NXP Semiconductors chairman sells 12K shares of common stock MITK Mitek Systems $16.85 / +0.71 (+4.40%) 12/04/20 Mitek Systems CFO Davison to retire 09/23/20 Mitek Systems, Nova Credit partner to help immigrants establish U.S. credit KMT Kennametal $39.05 / +1.2 (+3.17%) 02/01/21 Kennametal CEO says 'our transformation is well underway' 08/03/20 Kennametal sees FY21 CapEx $110M-$130M HLIT Harmonic $7.87 / +0.08 (+1.03%) 12/15/20 Harmonic's CableOS platform and services deployed by TWT Digital Communication 12/09/20 Harmonic's streaming and broadcast solution selected by Edge Networks 11/10/20 Harmonic's cloud platform selected by PVSC 10/26/20 Harmonic CEO sees 'strong business momentum through balance of the year' CURI CuriosityStream $17.80 / +0.39 (+2.24%) 10/14/20 CuriosityStream to begin trading on Nasdaq with ticker 'CURI' after closing deal CRUS Cirrus Logic $97.99 / +4.155 (+4.43%) 02/01/21 Cirrus Logic drops 7% to $90.50 after Q3 results, Q4 guidance 02/01/21 Cirrus Logic authorizes repurchase of up to additional $350M of common stock 11/02/20 Cirrus Logic jumps 8% to $72.00 after Q2 earnings beat, Q3 guidance 11/02/20 Cirrus Logic CEO Jason Rhode to step down effective January 1st AXTA Axalta Coating $27.77 / +0.77 (+2.85%) 02/01/21 Axalta Coating to delay Q4, FY earnings report 11/16/20 Jana Partners buys Encompass Health, exits Hillebrand in Q3 11/05/20 Axalta Coating launches new organizational structure 09/11/20 Berkshire Hathaway lowers Axalta Coating stake by 2% or $12.1M ARQT Arcutis Biotherapeutics $35.37 / +7.95 (+28.99%) 01/20/21 Arcutis to advance topical roflumilast foam into Phase 3 development 01/13/21 Arcutis initiaties Phase 3 clinical trials of topical roflumilast cream 01/11/21 Arcutis Biotherapeutics appoints Matthew Moore as CBO 12/21/20 Arcutis Biotherapeutics added to the Nasdaq Biotechnology Index SKY KMT HLIT CRUS RMBS WWD VRTX ARQT NXPI MITK CURI RVMD AXTA SKY Skyline Champion $34.99 / +1.29 (+3.83%) 12/18/20 Barclays Skyline price target raised to $36 from $32 at Barclays 12/18/20 Wedbush Skyline initiated with an Outperform at Wedbush 12/17/20 Wedbush Skyline initiated with an Outperform at Wedbush 05/21/20 Truist Skyline upgraded to Buy from Hold at SunTrust KMT Kennametal $39.05 / +1.2 (+3.17%) 01/15/21 Jefferies Kennametal price target raised to $48 from $40 at Jefferies 01/05/21 Barclays Kennametal price target raised to $35 from $33 at Barclays 12/29/20 Barclays Short cycle industrial risk/rewards more balanced into 2021, says Barclays 11/04/20 Fly Intel: Top five analyst downgrades HLIT Harmonic $7.87 / +0.08 (+1.03%) 01/14/21 Barclays Harmonic price target raised to $8 from $7 at Barclays 09/23/20 Colliers Harmonic opportunity in focus after SES partners with Microsoft, says Colliers 06/01/20 JPMorgan Harmonic downgraded to Neutral on spending pushouts at JPMorgan 06/01/20 JPMorgan Harmonic downgraded to Neutral from Overweight at JPMorgan CRUS Cirrus Logic $97.99 / +4.155 (+4.43%) 01/28/21 Oppenheimer Strength in Apple iPhone sales bodes well for Qorvo, Skyworks, says Oppenheimer 01/12/21 Susquehanna Susquehanna names top five M&A candidates in Semi space 01/08/21 Barclays Cirrus Logic price target raised to $90 from $70 at Barclays 01/06/21 KeyBanc Cirrus Logic upgraded to Overweight from Sector Weight at KeyBanc RMBS Rambus $19.55 / +0.51 (+2.68%) 01/25/21 Citi Rambus price target raised to $24 from $17 at Citi 01/12/21 Wells Fargo Intel's ramp of Ice Lake should be a boost for Rambus, says Wells Fargo 12/30/20 Roth Capital Rambus price target raised to $21 from $18 at Roth Capital 09/25/20 Citi KLA on top, Amkor at bottom of Citi's Semiconductor rankings WWD Woodward $115.35 / +3.32 (+2.96%) 01/11/21 Truist Woodward upgraded to Hold from Sell at Truist 12/13/20 Goldman Sachs Woodward initiated with a Neutral at Goldman Sachs 12/04/20 Barclays Woodward downgraded to Equal Weight from Overweight at Barclays 11/20/20 Truist Woodward price target raised to $70 from $51 at Truist VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 01/12/21 Truist Crispr Therapeutics price target raised to $210 from $170 at Truist 12/30/20 Fly Intel: Top five analyst calls 12/30/20 Daiwa Vertex Pharmaceuticals initiated with an Outperform at Daiwa 12/10/20 Oppenheimer Crispr Therapeutics price target raised to $165 from $155 at Oppenheimer ARQT Arcutis Biotherapeutics $35.37 / +7.95 (+28.99%) 02/01/21 Cowen Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen 01/28/21 JonesTrading Arcutis Biotherapeutics initiated with a Buy at JonesTrading 11/09/20 Goldman Sachs Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs 10/08/20 Truist Arcutis Biotherapeutics initiated with a Buy at Truist NXPI NXP Semiconductors $171.63 / +11.4 (+7.11%) 02/01/21 BMO Capital NXP Semiconductors price target raised to $168 from $142 at BMO Capital 01/26/21 Wells Fargo NXP Semiconductors price target raised to $200 from $180 at Wells Fargo 01/26/21 Barclays NXP Semiconductors price target raised to $200 from $150 at Barclays 01/15/21 Truist NXP Semiconductors price target raised to $209 from $165 at Truist MITK Mitek Systems $16.85 / +0.71 (+4.40%) 01/22/21 Maxim Mitek Systems initiated with a Buy at Maxim 12/04/20 Benchmark Mitek Systems CFO exit plan adds uncertainty, says Benchmark 08/24/20 William Blair Mitek long-term risk/reward prospects attractive, says William Blair 03/25/20 National Securities Mitek Systems upgraded to Buy from Neutral at National Securities CURI CuriosityStream $17.80 / +0.39 (+2.24%) 01/12/21 Benchmark CuriosityStream initiated with a Buy at Benchmark 01/06/21 B. Riley Securities B. Riley downgrades CuriosityStream after 'puzzling' 95% stock rally 01/06/21 B. Riley Securities CuriosityStream downgraded to Neutral from Buy at B. Riley Securities 12/21/20 Stifel CuriosityStream downgraded to Hold from Buy at Stifel RVMD Revolution Medicines $44.71 / +2.41 (+5.70%) 01/29/21 JPMorgan Revolution Medicines price target raised to $44 from $33 at JPMorgan 10/26/20 H.C. Wainwright Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright 09/14/20 Jefferies Inhibrx initiated with a Buy at Jefferies 05/21/20 Fly Intel: Top five analyst initiations AXTA Axalta Coating $27.77 / +0.77 (+2.85%) 01/15/21 KeyBanc Axalta Coating downgraded to Sector Weight from Overweight at KeyBanc 10/23/20 Deutsche Bank Axalta Coating price target raised to $30 from $26 at Deutsche Bank 10/20/20 Morgan Stanley Axalta Coating price target raised to $27 from $23 at Morgan Stanley 10/14/20 Fly Intel: Top five analyst upgrades WWD VRTX SKY RVMD RMBS NXPI MITK KMT HLIT CRUS AXTA ARQT WWD Woodward $115.35 / +3.32 (+2.96%) 02/01/21 Woodward reports Q1 adjusted EPS 64c, consensus 68c 11/19/20 Woodward not providing FY21 guidance due to effects associated with COVID-19 11/19/20 Woodward reports Q4 adj. EPS 75c, consensus 54c 08/06/20 Woodward sees Q4 results being similar to Q3 VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex Pharmaceuticals reports Q4 EPS $2.51, consensus $2.59 10/29/20 Vertex Pharmaceuticals reports Q3 EPS $2.64, consensus $2.34 10/29/20 Notable companies reporting after market close SKY Skyline Champion $34.99 / +1.29 (+3.83%) 02/01/21 Skyline Champion reports Q3 EPS 38c, consensus 24c 10/27/20 Skyline Champion reports Q2 adjusted EPS 31c, consensus 23c RVMD Revolution Medicines $44.71 / +2.41 (+5.70%) 11/12/20 Revolution Medicines reports Q3 EPS (42c), consensus (39c) 08/10/20 Revolution Medicines reports Q2 EPS (46c), consensus (35c) RMBS Rambus $19.55 / +0.51 (+2.68%) 02/01/21 Rambus reports Q4 EPS (11c), consensus 25c 11/02/20 Rambus reports Q3 GAAP EPS (11c), consensus 27c 08/03/20 Rambus reports Q2 GAAP EPS (9c), consensus 25c NXPI NXP Semiconductors $171.63 / +11.4 (+7.11%) 02/01/21 NXP Semiconductors sees Q1 revenue $2.48B-$2.55B, consensus $2.31B 02/01/21 NXP Semiconductors reports Q4 EPS $1.08, consensus $2.10 10/26/20 NXP Semiconductors reports Q3 EPS (8c) vs. 38c a year ago 10/26/20 NXP Semiconductors sees Q4 adjusted operating income $692M-$766M MITK Mitek Systems $16.85 / +0.71 (+4.40%) 01/28/21 Mitek Systems reports Q1 EPS 14c, consensus 13c 11/05/20 Mitek Systems reports Q4 EPS 26c, consensus 14c KMT Kennametal $39.05 / +1.2 (+3.17%) 02/01/21 Kennametal says not providing FY21 outlook at this time 02/01/21 Kennametal reports Q2 adjusted EPS 16c, consensus 9c 11/02/20 Kennametal not providing FY21 guidance 11/02/20 Kennametal reports Q1 adjusted EPS 3c, consensus 6c HLIT Harmonic $7.87 / +0.08 (+1.03%) 02/01/21 Harmonic sees FY21 non-GAAP EPS 9c-31c, consensus 35c 02/01/21 Harmonic sees Q1 non-GAAP EPS 0c-4c, consensus 3c 02/01/21 Harmonic reports Q4 non-GAAP EPS 20c, consensus 15c 10/26/20 Harmonic sees FY20 adjusted EPS (3c)-4c, consensus (4c) CRUS Cirrus Logic $97.99 / +4.155 (+4.43%) 02/01/21 Cirrus Logic sees Q4 revenue $280M-$320M, consensus $297.84M 02/01/21 Cirrus Logic reports Q3 adjusted EPS $2.13, consensus $1.86 02/01/21 Notable companies reporting after market close 11/02/20 Cirrus Logic sees Q3 revenue $440M-$480M, consensus $354.42M AXTA Axalta Coating $27.77 / +0.77 (+2.85%) 02/01/21 Axalta Coating reports preliminary Q4 revenue $1.075B, consensus $1.03B 10/21/20 Notable companies reporting before tomorrow's open 10/21/20 Axalta Coating sees FY20 adjusted EPS $1.15-$1.20, consensus 87c 10/21/20 Axalta Coating reports Q3 adjusted EPS 59c, consensus 33c ARQT Arcutis Biotherapeutics $35.37 / +7.95 (+28.99%) 11/05/20 Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c) 08/11/20 Arcutis Biotherapeutics reports Q2 EPS (94c), consensus (84c) 03 Feb 04 Feb 02 Oct 09 Jul 13 Feb VRTX MITK VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says 10/09/20 Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports MITK Mitek Systems $16.85 / +0.71 (+4.40%) 08/27/20 Mitek picked by HSBC for biometric verification technology, Bank Innovation says VRTX SKY RMBS NXPI MITK HLIT CURI CRUS AXTA ARQT VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 12/07/20 Crispr rises following ASH update for genome editing cell therapy candidate 10/15/20 Fly Intel: Wall Street's top stories for Thursday 10/15/20 Fly Intel: Wall Street's top stories at midday SKY Skyline Champion $34.99 / +1.29 (+3.83%) 02/01/21 Fly Intel: After-Hours Movers 10/27/20 Fly Intel: After-Hours Movers RMBS Rambus $19.55 / +0.51 (+2.68%) 08/03/20 Fly Intel: After-Hours Movers NXPI NXP Semiconductors $171.63 / +11.4 (+7.11%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 12/15/20 Wells Fargo upgrade, Dick's Sporting initiation among top calls on Wall Street MITK Mitek Systems $16.85 / +0.71 (+4.40%) 01/28/21 Fly Intel: After-Hours Movers HLIT Harmonic $7.87 / +0.08 (+1.03%) 10/26/20 Fly Intel: After-Hours Movers 08/04/20 Fly Intel: Wall Street's top stories for Tuesday 08/04/20 Fly Intel: Wall Street's top stories at midday CURI CuriosityStream $17.80 / +0.39 (+2.24%) 01/06/21 Fly Intel: Pre-market Movers CRUS Cirrus Logic $97.99 / +4.155 (+4.43%) 01/12/21 On, Lumentum seen among top semiconductors takeout candidates for 2021 11/02/20 Fly Intel: After-Hours Movers AXTA Axalta Coating $27.77 / +0.77 (+2.85%) 10/22/20 Fly Intel: Pre-market Movers 10/21/20 Fly Intel: After-Hours Movers ARQT Arcutis Biotherapeutics $35.37 / +7.95 (+28.99%) 10/12/20 Fly Insider: Element Solutions, Sunrun among week's notable insider trades 09/29/20 Fly Intel: After-Hours Movers 02/10/21 42nd Annual Aerospace/Defense & Industrials Virtual Conference 00:00 Today 41st Annual Healthcare Virtual Conference 03/15/21 33rd Annual Roth Virtual Conference 02/01/21 Woodward - WWD 02/01/21 Vertex Pharmaceuticals - VRTX 02/01/21 Cirrus Logic - CRUS 02/01/21 Harmonic - HLIT 02/01/21 Rambus - RMBS 02/02/21 Kennametal - KMT 02/02/21 NXP Semiconductors - NXPI 02/02/21 Skyline Champion - SKY 02/18/21 Axalta Coating - AXTA 06/08/21 PDUFA Date for TRIKAFTA 02/09/21 Skyline Champion 03/03/21 Mitek Systems, Inc. VRTX RVMD RMBS NXPI CRUS AXTA ARQT VRTX Vertex Pharmaceuticals $231.79 / +2.77 (+1.21%) 02/01/21 Vertex options imply 7.0% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th 10/28/20 Vertex call volume above normal and directionally bullish 10/16/20 Early notable gainers among liquid option names on October 16th RVMD Revolution Medicines $44.71 / +2.41 (+5.70%) 11/25/20 new option listings on November 25th RMBS Rambus $19.55 / +0.51 (+2.68%) 02/01/21 Rambus options imply 7.5% move in share price post-earnings NXPI NXP Semiconductors $171.63 / +11.4 (+7.11%) 02/01/21 NXP Semiconductors options imply 8.7% move in share price post-earnings 10/01/20 NXP Semiconductors put volume heavy and directionally bearish 09/08/20 NXP Semiconductors put volume heavy and directionally bearish 09/04/20 NXP Semiconductors put volume heavy and directionally bearish CRUS Cirrus Logic $97.99 / +4.155 (+4.43%) 02/01/21 Cirrus Logic options imply 12.4% move in share price post-earnings AXTA Axalta Coating $27.77 / +0.77 (+2.85%) 01/26/21 Axalta Coating call volume above normal and directionally bullish 10/01/20 Axalta Coating call volume above normal and directionally bullish 09/04/20 Unusually active option classes on open September 4th ARQT Arcutis Biotherapeutics $35.37 / +7.95 (+28.99%) 01/21/21 Eighteen new option listings and one option delisting on January 21st

On The Fly

News and insights, exclusive to thefly.com

20:25	Notable companies reporting before tomorrow's open»
16:38	JPMorgan downgrades Athenex on 'huge surprise' from FDA»
13:49	Notable companies reporting before tomorrow's open»
13:47	Notable companies reporting after market close»
12:48	Morphic Holding price target raised to $103 from $40 at Wells Fargo»

View all On The Fly Stories »

Upcoming
Events (10)

KMPH	PDUFA Date for KP415
AOSL	Alpha & Omega - AOSL
UEPS	Net 1 UEPS - UEPS
SAIL ...	Technology, Media & Telecom Virtual Conference
	Global Environmental, Social & Governance Virtual Conference 2021
	26th Annual Energy Virtual Summit
AFMD ...	2021 London Global Healthcare Virtual Conference
	42nd Annual Institutional Investors Virtual Conference
	Technology Virtual Conference 2021
BNR ...	41st Annual Healthcare Virtual Conference

View all of today’s events »

Today’s
Syndicate (9)

SWTX	Block Trade
KRTX	Secondary
EAF	Spot Secondary
FRC	Spot Secondary
HLNE	Spot Secondary
JELD	Spot Secondary
RDHL	Spot Secondary
SITC	Spot Secondary
WSC	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial